<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atropine (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atropine (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atropine (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="103444" href="/d/html/103444.html" rel="external">see "Atropine (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="103446" href="/d/html/103446.html" rel="external">see "Atropine (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F28564711"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AtroPen [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F28625003"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Anticholinergic Agent</span>;</li>
<li>
<span class="list-set-name">Antidote, Organophosphate Poisoning</span>;</li>
<li>
<span class="list-set-name">Antispasmodic Agent, Gastrointestinal</span>;</li>
<li>
<span class="list-set-name">Bronchodilator</span></li></ul></div>
<div class="block don drugH1Div" id="F53462691"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6254e0b0-d1a0-4413-b531-666b66a5a03e">Bradycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia: Note:</b> Neonatal resuscitation guidelines do not include atropine for the treatment of bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956432'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV, Intraosseous: 0.02 mg/kg/dose; may repeat once in 3 to 5 minutes; reserve use for patients unresponsive to improved oxygenation/ventilation and epinephrine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>); use of a minimum dose of 0.1 mg in patients &lt;5 kg will result in dosages &gt;0.02 mg/kg; in some cases toxicity and even death have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21382950','lexi-content-ref-4621205','lexi-content-ref-26019366','lexi-content-ref-15081189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21382950','lexi-content-ref-4621205','lexi-content-ref-26019366','lexi-content-ref-15081189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Endotracheal: 0.04 to 0.06 mg/kg/dose; immediately follow with 1 mL of NS; may repeat once if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0917de5c-6b0d-49c8-88b2-5939a4a36614">Intubation, premedication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intubation, premedication (preferred vagolytic):</b> IV, IM: 0.02 mg/kg/dose; a minimum dose of 0.1 mg/dose is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kumar.1','lexi-content-ref-21382950','lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kumar.1','lexi-content-ref-21382950','lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6043d75d-1c02-4284-b890-c942ce51fc24">Organophosphate or carbamate insecticide or nerve agent poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate or carbamate insecticide or nerve agent poisoning: Note:</b> If exposure is known or suspected, antidotal therapy should be given as soon as symptoms appear; do not wait for confirmation. The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; ≥2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous IV infusion in patients requiring large doses of atropine. Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to pralidoxime for the specific route and dose.</p>
<p style="text-indent:-2em;margin-left:4em;">IV, IM, Intraosseous: Initial: 0.05 to 0.1 mg/kg; repeat every 3 to 5 minutes as needed, double the dose if previous dose did not induce atropinization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23184105','lexi-content-ref-31871244','lexi-content-ref-Howland.1','lexi-content-ref-Roberts.1','lexi-content-ref-12949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23184105','lexi-content-ref-31871244','lexi-content-ref-Howland.1','lexi-content-ref-Roberts.1','lexi-content-ref-12949297'])">Ref</a></span>). Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Roberts.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Roberts.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Following atropinization, administer 10% to 20% of the total loading dose required to induce atropinization as a continuous IV infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15566582','lexi-content-ref-17379909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15566582','lexi-content-ref-17379909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM (AtroPen): 0.25 mg (yellow pen):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild symptoms (≥2 mild symptoms):</i> Administer one 0.25 mg (yellow pen) dose as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe symptoms (≥1 severe symptom):</i> Immediately administer <b>three</b> 0.25 mg (yellow pen) doses. Severe symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary); <b>Note:</b> Neonates and infants may become drowsy or unconscious with muscle floppiness as opposed to muscle twitching.</p>
<p style="text-indent:-2em;margin-left:4em;">Endotracheal: Increase the dose by 2 to 3 times the usual IV dose. Mix with 3 to 5 mL of normal saline and administer. Flush with 3 to 5 mL of NS and follow with 5 assisted manual ventilations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12949297'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F28406321"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6254e0b0-d1a0-4413-b531-666b66a5a03e">Bradycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV, Intraosseous: 0.02 mg/kg/dose; minimum dose: 0.1 mg/dose, maximum dose: 0.5 mg/dose; may repeat once in 5 minutes; reserve use for those patients unresponsive to improved oxygenation and epinephrine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26471384','lexi-content-ref-20956230','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26471384','lexi-content-ref-20956230','lexi-content-ref-33081526'])">Ref</a></span>); some have suggested the minimum dose should not be used in patients &lt;5 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21382950','lexi-content-ref-28781474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21382950','lexi-content-ref-28781474'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Endotracheal: 0.04 to 0.06 mg/kg/dose; may repeat once if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26471384','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26471384','lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e9692e8-90ec-492b-af9e-a98ff4530a3f">Inhibit salivation and secretions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inhibit salivation and secretions (preoperative/intraoperative):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years: IM, IV, SUBQ: 0.02 mg/kg/dose; maximum dose: 0.5 mg/dose; administer first dose 30 to 60 minutes preoperatively and then repeat every 4 to 6 hours as needed; maximum <b>total</b> dose: 1 mg/procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IM, IV, SUBQ: 0.02 mg/kg/dose; maximum dose: 1 mg/dose; administer first dose 30 to 60 minutes preoperatively and then repeat every 4 to 6 hours as needed; maximum <b>total</b> dose: 2 mg/procedure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="08a02b18-4166-4301-9fad-6d86783a9c3a">Intubation; emergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intubation; emergent (premedication): Note:</b> Routine use not recommended for preintubation in infants and children; atropine may be considered in situations with a high-risk of bradycardia (eg, succinylcholine use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26471384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26471384'])">Ref</a></span>) or septic shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19325359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19325359'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: IV: 0.02 mg/kg/dose with no minimum dose; maximum dose: 0.5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26471384','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26471384','lexi-content-ref-33081526'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d69b6ae-d471-496b-b60e-eace1c23cbf7">Muscarine-containing mushroom poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Muscarine-containing mushroom poisoning:</b> Limited data available: Infants, Children, and Adolescents: IV: 0.02 mg/kg/dose; minimum dose: 0.1 mg. Titrate and repeat as needed to reverse symptoms (ie, titrate to achieve decreased bronchial secretions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldfrank.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldfrank.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6043d75d-1c02-4284-b890-c942ce51fc24">Organophosphate or carbamate insecticide or nerve agent poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate or carbamate insecticide or nerve agent poisoning:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> If exposure is known or suspected, antidotal therapy should be given as soon as symptoms appear; do not wait for confirmation. The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; ≥2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous IV infusion in patients requiring large doses of atropine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25455666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25455666'])">Ref</a></span>). Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to pralidoxime for the specific route and dose.</p>
<p style="text-indent:-2em;margin-left:4em;">IV, IM, Intraosseous (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Initial: 0.05 to 0.1 mg/kg; repeat every 3 to 5 minutes as needed, double the dose if previous dose does not induce atropinization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23184105','lexi-content-ref-31871244','lexi-content-ref-Roberts.1','lexi-content-ref-12949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23184105','lexi-content-ref-31871244','lexi-content-ref-Roberts.1','lexi-content-ref-12949297'])">Ref</a></span>). Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Roberts.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Roberts.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Initial: 1 to 3 mg; repeat every 3 to 5 minutes as needed, doubling the dose if previous dose does not induce atropinization. Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Roberts.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Roberts.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Infants, Children, and Adolescents: Following atropinization, administer 10% to 20% of the total loading dose required to induce atropinization as a continuous IV infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15566582','lexi-content-ref-17379909','lexi-content-ref-Roberts.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15566582','lexi-content-ref-17379909','lexi-content-ref-Roberts.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM (AtroPen): Infants, Children, and Adolescents: Number of doses dependent upon symptom severity:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;7 kg (&lt;15 lb): 0.25 mg/dose (yellow pen).</p>
<p style="text-indent:-2em;margin-left:8em;">7 to 18 kg (15 to 40 lb): 0.5 mg/dose (blue pen).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;18 to 41 kg (&gt;40 to 90 lb): 1 mg/dose (dark red pen).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;41 kg (&gt;90 lb): 2 mg/dose (green pen).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mild symptoms (≥2 mild symptoms):</i> Administer the weight-directed dose listed above as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe symptoms (≥1 severe symptom):</i> Immediately administer <b>three</b> weight-directed doses in rapid succession (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>). Severe symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary); <b>Note:</b> Infants may become drowsy or unconscious with muscle floppiness as opposed to muscle twitching.</p>
<p style="text-indent:-2em;margin-left:4em;">Endotracheal: Infants, Children, and Adolescents: Increase the dose by 2 to 3 times the usual IV dose. Mix with 3 to 5 mL of normal saline and administer. Flush with 3 to 5 mL of NS and follow with 5 assisted manual ventilations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12949297'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51073333"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51073334"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F28406322"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="103444" href="/d/html/103444.html" rel="external">see "Atropine (systemic): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> IV doses &lt;0.5 mg have been associated with paradoxical bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1778541','lexi-content-ref-786681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1778541','lexi-content-ref-786681'])">Ref</a></span>). Restrict total dose to 0.03 to 0.04 mg/kg in patients with ischemic heart disease.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0996065-58db-4c01-8979-d77153648c02">Bradycardia during neuromuscular blockade reversal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia during neuromuscular blockade reversal:</b>
<b>IV:</b> 5 to 7 mcg/kg when administered with edrophonium or 15 to 20 mcg/kg when administered with neostigmine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7125261','lexi-content-ref-Gropper.1','lexi-content-ref-7196168','lexi-content-ref-2758540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7125261','lexi-content-ref-Gropper.1','lexi-content-ref-7196168','lexi-content-ref-2758540'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09c3257a-57c8-4d84-b7ff-6bc34c7d5d88">Bradycardia, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia, symptomatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Atropine is ineffective in heart transplant recipients due to lack of vagal innervation and likely not effective for type II second-degree or third-degree atrioventricular node block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hazinski.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hazinski.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b> 0.5 to 1 mg every 3 to 5 minutes; 1 mg is preferred for severe bradyarrhythmias (eg, hypotension/shock, altered mental status, acute heart failure); maximum total dose: 3 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412709','lexi-content-ref-33081529','lexi-content-ref-AHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412709','lexi-content-ref-33081529','lexi-content-ref-AHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Endotracheal:</b> 1 to 2 mg every 3 to 5 minutes.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e9692e8-90ec-492b-af9e-a98ff4530a3f">Inhibit salivation and secretions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inhibit salivation and secretions (preanesthesia):</b>
<b>IM, IV, SUBQ: </b>0.5 to 1 mg 30 to 60 minutes before procedure; repeat every 4 to 6 hours as needed; maximum total dose: 3 mg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d69b6ae-d471-496b-b60e-eace1c23cbf7">Muscarine-containing mushroom poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Muscarine-containing mushroom poisoning (off-label dose):</b>
<b>IV:</b> 1 to 2 mg; titrate and repeat as needed to reverse symptoms (ie, titrate to achieve decreased bronchial secretions) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldfrank.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldfrank.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6043d75d-1c02-4284-b890-c942ce51fc24">Organophosphate or carbamate insecticide or nerve agent poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Organophosphate or carbamate insecticide or nerve agent poisoning: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; ≥2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous IV infusion in patients requiring large doses of atropine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25455666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25455666'])">Ref</a></span>). Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is an essential component of the management of organophosphate insecticide and nerve agent toxicity; refer to Pralidoxime monograph for the specific route and dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate symptoms: Initial: 1 to 2 mg bolus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>); repeat by doubling the dose every 3 to 5 minutes if previous dose did not induce a response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15566582','lexi-content-ref-17379909','lexi-content-ref-24091052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15566582','lexi-content-ref-17379909','lexi-content-ref-24091052'])">Ref</a></span>). Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reigart.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reigart.1'])">Ref</a></span>). After the desired response is achieved with bolus dosing, consider starting an IV continuous infusion for improved clinical outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22351300','lexi-content-ref-15566582','lexi-content-ref-17379909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22351300','lexi-content-ref-15566582','lexi-content-ref-17379909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe symptoms: Initial: 3 to 5 mg bolus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>); repeat by doubling the dose every 3 to 5 minutes if previous dose did not induce a response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15566582','lexi-content-ref-17379909','lexi-content-ref-24091052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15566582','lexi-content-ref-17379909','lexi-content-ref-24091052'])">Ref</a></span>). Maintain atropinization by administering repeat doses as needed for ≥2 to 12 hours based on recurrence of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Reigart.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Reigart.1'])">Ref</a></span>). After the desired response is achieved with bolus dosing, consider starting an IV continuous infusion for improved clinical outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22351300','lexi-content-ref-15566582','lexi-content-ref-17379909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22351300','lexi-content-ref-15566582','lexi-content-ref-17379909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV continuous infusion:</b> After desired response is achieved with IV boluses, administer 10% to 20% of the total cumulative IV bolus dose as an IV continuous infusion per hour (eg, if 18 mg given by IV bolus is required to achieve the desired response, start an IV continuous infusion of 1.8 mg per hour); adjust infusion rate as needed to maintain adequate response without causing atropine toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22351300','lexi-content-ref-15566582','lexi-content-ref-17379909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22351300','lexi-content-ref-15566582','lexi-content-ref-17379909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (AtroPen):</b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild symptoms (≥2 mild symptoms): Administer 2 mg as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe symptoms (≥1 severe symptoms): Immediately administer <b>three</b> 2 mg doses in rapid succession.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling, to guide therapy:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Mild symptoms: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.</p>
<p style="text-indent:-2em;margin-left:8em;">Severe symptoms: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Endotracheal:</b> Usual dose: 2 to 2.5 times IV dose diluted in 5 to 10 mL of 0.9% sodium chloride or sterile water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f95a5d5-40d2-4908-b6cc-088d7239878a">Stress echocardiography</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress echocardiography (adjunctive agent) (diagnostic agent) (off-label use):</b>
<b>IV:</b> 0.25 to 0.5 mg every 1 minute as needed until 85% of age-predicted maximum heart rate is achieved; maximum total dose: 1 to 2 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31740370','lexi-content-ref-26914678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31740370','lexi-content-ref-26914678'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990679"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987957"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F28406293"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined. Severity and frequency of adverse reactions are dose related.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Asystole, atrial arrhythmia, atrial fibrillation, atrioventricular dissociation (transient), bigeminy, bradycardia, chest pain, decreased blood pressure, ECG changes (prolonged P wave, shortened PR segment, R on T phenomenon, shortened RT duration, prolonged QT interval, widening of QRS Complex, flattened T wave, repolarization abnormalities, ST segment elevation, retrograde conduction), ectopic beats (atrial), extrasystoles (nodal, ventricular, supraventricular), flushing, increased blood pressure, left heart failure, myocardial infarction, nodal arrhythmia (no P wave on ECG), palpitations, sinus tachycardia, supraventricular tachycardia (including junctional tachycardia), tachycardia, trigeminy, ventricular arrhythmia (including flutter), ventricular fibrillation, ventricular flutter, ventricular premature contractions, ventricular tachycardia, weak pulse (or impalpable peripheral pulses)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Abnormal electroencephalogram (runs of alpha waves, increase in photic stimulation, and signs of drowsiness), agitation (children), amnesia, anxiety, ataxia, behavioral changes, coma, confusion, decreased deep tendon reflex, delirium, dizziness, drowsiness, dysarthria, dysmetria, emotional disturbance, excitement, feeling hot, hallucination (visual or aural), headache, hyperpyrexia, hyperreflexia, hypertonia, insomnia, intoxicated feeling, irritability (children), lack of concentration, lethargy (children), mania, myoclonus, neurologic abnormality, nocturnal enuresis, opisthotonus, paranoia, positive Babinski sign, restlessness, seizure (generally tonic-clonic), stupor, vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Anhidrosis, cold skin, dermatitis, dry and hot skin, erythematous rash, hyperhidrosis, macular eruption, maculopapular rash, papular rash, scarlatiniform rash, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Dehydration, hyperglycemia, hypoglycemia, hypokalemia, hyponatremia, increased thirst, loss of libido</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal and bladder distension, abdominal pain, constipation, delayed gastric emptying, diminished bowel sounds, dry mucous membranes, dysphagia, malabsorption, nausea, oral lesion, paralytic ileus, salivation, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Difficulty in micturition, impotence, urinary hesitancy, urinary retention, urinary urgency</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Abnormal erythrocytes (increased), decreased hemoglobin, increased hemoglobin, leukocytosis, petechiae</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Laryngospasm, muscle twitching, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Abnormal eye movements (cyclophoria and heterophoria), angle-closure glaucoma (acute), blepharitis, blindness, blurred vision, conjunctivitis, crusted of eyelid, cycloplegia, decreased accommodation, decreased visual acuity, dry eye syndrome, eye irritation, lacrimation, mydriasis, photophobia, strabismus</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Increased blood urea nitrogen</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Bradypnea, changes in respiration (labored respiration), cyanosis, dyspnea, laryngitis, pulmonary edema, respiratory failure, stridor (inspiratory), tachypnea</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Failure to thrive, fever (secondary to decreased sweat gland activity), swelling (children)</p></div>
<div class="block coi drugH1Div" id="F28406290"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer’s US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to atropine or any component of the formulation; GI obstruction, glaucoma (known or suspected), pyloric stenosis or prostatic hypertrophy (except in doses typically used for preanesthesia).</p></div>
<div class="block war drugH1Div" id="F28406291"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including anaphylactic reactions, may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthermia: Atropine may inhibit sweating and possibly lead to heat-related injury or hyperthermia in patients exposed to warm environments or exercise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Can occur in sensitive individuals or following use of excessive doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Avoid relying on atropine for effective treatment of type II second-degree or third-degree AV block (with or without a new wide QRS complex). Asystole or bradycardic PEA: Although no evidence exists for significant detrimental effects, routine use is unlikely to have a therapeutic benefit and is no longer recommended (ACLS 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with myocardial ischemia, heart failure, tachyarrhythmias (including sinus tachycardia), and/or hypertension; treatment-related blood pressure increases and tachycardia may lead to ischemia, precipitate an MI, or increase arrhythmogenic potential.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic lung disease: Use with caution in patients with chronic lung disease; may cause thickening of bronchial secretions and formation of dangerous viscid plugs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with severe narrow-angle glaucoma; may precipitate acute glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; effects of atropine may be prolonged in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hiatal hernia: Use with caution in patients with hiatal hernia associated with reflux esophagitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with extreme caution when used to treat side effects of acetylcholinesterase inhibition or avoid; may precipitate a myasthenic crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropathy: Use with caution in patients with autonomic neuropathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pyloric stenosis: Use with caution in patients with partial pyloric stenosis; may cause complete pyloric obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; effects of atropine may be prolonged in severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention: Use with caution in patients with urinary obstruction; may cause urinary retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart transplant recipients: Atropine will likely be ineffective in treatment of bradycardia due to lack of vagal innervation of the transplanted heart. Cholinergic reinnervation may occur over time (years), so atropine may be used cautiously; however, some may experience paradoxical slowing of the heart rate and high-degree AV block upon administration (ACLS 2010; Bernheim 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children may be more sensitive to the anticholinergic effects of atropine. Use with caution in children with spastic paralysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Anticholinesterase poisoning: Atropine reverses the muscarinic but not the nicotinic effects associated with anticholinesterase toxicity. Clinical symptoms consistent with highly-suspected organophosphate or carbamate insecticides or nerve agent poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests. Signs of atropinization include flushing, mydriasis, tachycardia, and dryness of the mouth or nose. Monitor effects closely when administering subsequent injections as necessary. The presence of these effects is not indicative of the success of therapy; inappropriate use of mydriasis as an indicator of successful treatment has resulted in atropine toxicity. Reversal of bronchial secretions is the preferred indicator of success. Adjunct treatment with a cholinesterase reactivator (eg, pralidoxime) may be required in patients with toxicity secondary to organophosphorus insecticides or nerve agents. Treatment should always include proper evacuation and decontamination procedures; medical personnel should protect themselves from inadvertent contamination. Antidotal administration is intended only for initial management; definitive and more extensive medical care is required following administration. Individuals should not rely solely on antidote for treatment, as other supportive measures (eg, artificial respiration) may still be required.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878800"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Several reports in the literature have described neonates developing central anticholinergic syndrome after receiving atropine for bradycardia at doses of 0.1 mg, the minimum dose that has been described for preventing paradoxical bradycardia. When evaluated based on weight, this dose exceeded 0.02 mg/kg in all cases (Gillick 1974; Prakash 2017; Rizzi 2004); some literature has recommended against using a minimum dose in patients &lt;5 kg to prevent overdose (Barrington 2011; Prakash 2017).</p></div>
<div class="block foc drugH1Div" id="F28406340"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg/mL (1 mL [DSC]); 1 mg/mL (1 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg/mL (1 mL); 1 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Intramuscular, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AtroPen: 0.5 mg/0.7 mL (0.7 mL [DSC]); 1 mg/0.7 mL (0.7 mL [DSC]); 2 mg/0.7 mL (0.7 mL [DSC]) [pyrogen free; contains phenol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Intramuscular, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AtroPen: 0.25 mg/0.3 mL (0.3 mL [DSC]) [pyrogen free]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg/5 mL (5 mL); 0.5 mg/5 mL (5 mL); 1 mg/10 mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F28406278"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F28406343"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Atropine Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg/20 mL (per mL): $2.11 - $4.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Atropine Sulfate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg/mL (per mL): $12.96 - $14.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $20.35 - $22.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Atropine Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/5 mL (per mL): $3.34 - $5.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/5 mL (per mL): $2.18 - $3.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/10 mL (per mL): $1.12 - $2.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871932"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.6 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1 mg/mL (10 mL); 0.4 mg/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/5 mL (5 mL); 1 mg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/5 mL ([DSC])</p></div>
<div class="block accres drugH1Div" id="F28406268"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">The AtroPen formulation is available for use primarily by the Department of Defense.</p></div>
<div class="block admp drugH1Div" id="F52614592"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Endotracheal: May administer dose undiluted, followed by flush with 1 to 5 mL of NS after endotracheal administration or may further dilute in NS or sterile water prior to administration (ie, 1 to 2 mg in ≤10 mL of NS or sterile water); follow with 5 assisted manual ventilations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-20956230','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-20956230','lexi-content-ref-Manu.1'])">Ref</a></span>). If using for cardiac arrest, stop compressions during drug administration and resume chest compressions following manual ventilation.</p>
<p style="text-indent:-2em;margin-left:4em;">Flush volume based on indication:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bradycardia: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Neonates: Flush with ≥1 mL NS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Flush with 5 mL NS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Organophosphate or carbamate insecticide or nerve agent poisoning:</i> Flush with 3 to 5 mL NS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12949297'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer undiluted by rapid IV injection; slow injection may result in paradoxical bradycardia.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: AtroPen: Administer to the outer thigh. Firmly grasp the autoinjector with the green tip (0.5 mg, 1 mg, and 2 mg autoinjector) or black tip (0.25 mg autoinjector) pointed down; remove the yellow safety release (0.5 mg, 1 mg, and 2 mg autoinjector) or gray safety release (0.25 autoinjector). Firmly jab the green tip at a 90° angle against the outer thigh; may be administered through clothing as long as pockets at the injection site are empty. In thin patients or patients &lt;6.8 kg (15 lb), bunch up the thigh prior to injection. Hold the autoinjector in place for 10 seconds following the injection; remove the autoinjector and massage the injection site. After administration, the needle will be visible; if the needle is not visible, repeat the above steps with more pressure. After use, bend the needle against a hard surface (needle does not retract) to avoid accidental injury.</p></div>
<div class="block adm drugH1Div" id="F28406327"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> AtroPen: Administer to the outer thigh. Firmly grasp the autoinjector with the green tip (0.5 mg, 1 mg, and 2 mg autoinjector) or black tip (0.25 mg autoinjector) pointed down; remove the yellow safety release (0.5 mg, 1 mg, and 2 mg autoinjector) or gray safety release (0.25 autoinjector). Jab the green tip at a 90° angle against the outer thigh; may be administered through clothing as long as pockets at the injection site are empty. In thin patients, bunch up the thigh prior to injection. Hold the autoinjector in place for 10 seconds following the injection; remove the autoinjector and massage the injection site. After administration, the needle will be visible; if the needle is not visible, repeat the above steps. After use, bend the needle against a hard surface (needle does not retract) to avoid accidental injury.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer undiluted by rapid IV injection; slow injection may result in paradoxical bradycardia. In bradycardia, atropine administration should not delay treatment with external pacing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraosseous (IO):</b> May administer intraosseous if needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal:</b> Dilute in ≤10 mL NS or sterile water. Absorption may be greater with sterile water. Stop compressions (if using for cardiac arrest), spray the drug quickly down the tube. Follow immediately with several quick insufflations and continue chest compressions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> May administer subcutaneous if needed.</p></div>
<div class="block sts drugH1Div" id="F28406305"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store injection at room temperature; avoid freezing. After initial use of multiple-dose vial, discard within 24 hours. In addition, AtroPen should be protected from light. Preparation of bulk atropine solution for mass chemical terrorism at a concentration of 1 mg/mL is stable for 72 hours at 4°C to 8°C (39°F to 46°F); 20°C to 25°C (68°F to 77°F); 32°C to 36°C (90°F to 97°F) (Dix 2003).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Guidelines suggest that at least 45 to 165 mg be stocked. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period; actual amount to stock should take into account site-specific and population-specific needs. Hospitals serving agricultural regions where organophosphate or carbamate insecticides are used should ensure that they maintain adequate supplies (Dart 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">In severe poisonings, the amount needed may exceed the standard recommendation (Dart 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">Mass casualty event secondary to an acetylcholinesterase inhibitor: In the unlikely occurrence of a mass casualty event secondary to an acetylcholinesterase inhibitor, supplies of atropine may rapidly deplete, including predeployed CHEMPACK containers. Both the FDA and the American College of Medical Toxicology recommend the use of expired medications, including auto-injectors, if needed in this situation (FDA 2021; Stolbach 2018). Consider stocking atropine as a ≥5 g bulk pharmaceutical grade powder in order to prepare large quantities of atropine solution for administration after an act of terrorism involving a nerve agent (Dix 2003).</p></div>
<div class="block usep drugH1Div" id="F53571240"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">Auto-injector: Antidote for anticholinesterase poisoning (carbamate insecticides, nerve agents, organophosphate insecticides, muscarinic poisoning) (FDA approved in all ages)</p>
<p style="text-indent:-2em;margin-left:4em;">Injection: Preoperative and intraoperative medication to inhibit salivation and secretions; treatment of symptomatic sinus bradycardia, AV nodal block, and bradyasystolic cardiac arrest; antidote for anticholinesterase poisoning (carbamate insecticides, nerve agents, organophosphate insecticides, muscarinic poisoning) (All indications: FDA approved in pediatric patients [age not specified] and adults); <b>Note:</b> Likely not effective for type II second-degree or third-degree AV block with wide QRS complexes; atropine has no effect on bradycardia in transplanted hearts. Use is no longer recommended in the management of asystole or pulseless electrical activity (PEA) (ACLS 2010). Approved ages and uses for generic products may vary; consult labeling for specific information.</p></div>
<div class="block mst drugH1Div" id="F28564710"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Atropine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its highly anticholinergic properties and uncertain effectiveness as an antispasmodic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F28406300"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F28406297"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Atropine (Systemic) may enhance the hypertensive effect of Alpha1-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Atropine (Systemic) may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Atropine (Systemic) may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Atropine (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Atropine (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F28406287"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Atropine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>
<div class="block mopp drugH1Div" id="F53571241"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, blood pressure, pulse, mental status; intravenous administration requires a cardiac monitor</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Organophosphate or carbamate insecticide or nerve agent poisoning:</i> Heart rate, blood pressure, respiratory status, oxygenation secretions. Maintain atropinization with repeated dosing as indicated by clinical status. Crackles in lung bases, or continuation of cholinergic signs, may be signs of inadequate dosing. Pulmonary improvement may not parallel other signs of atropinization. Monitor for signs and symptoms of atropine toxicity (eg, fever, muscle fasciculations, delirium); if toxicity occurs, discontinue atropine and monitor closely.</p>
<p style="text-indent:0em;margin-top:2em;">Consult individual institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F28406309"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; increases cardiac output, dries secretions. Atropine reverses the muscarinic effects of cholinergic poisoning due to agents with acetylcholinesterase inhibitor activity by acting as a competitive antagonist of acetylcholine at muscarinic receptors. The primary goal in cholinergic poisonings is reversal of bronchorrhea and bronchoconstriction. Atropine has no effect on the nicotinic receptors responsible for muscle weakness, fasciculations, and paralysis; concurrent administration of pralidoxime is necessary to reverse the nicotinic effects associated with organophosphate insecticide or nerve agent toxicity.</p></div>
<div class="block phk drugH1Div" id="F28406311"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Inhibition of salivation: IM: Within 30 minutes; maximum effect: 30 to 60 minutes (Mirakhur 1980; Volz-Zang 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Increased heart rate:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: Within 15 to 30 minutes (Kentala 1990; Volz-Zang 1995); maximum effect: 45 to 60 minutes (Mirakhur 1980; Volz-Zang 1995)</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Immediate; maximum effect: 0.7 to 4 minutes (Lonnerholm 1975; Santini 1999)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Inhibition of salivation: IM: ≤4 hours (Mirakhur 1980; Volz-Zang 1995)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and well absorbed from all dosage forms</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely throughout the body; crosses blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 14% to 44%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via enzymatic hydrolysis</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children &lt;2 years: 6.9 ± 3 hours; Children &gt;2 years: 2.5 ± 1.2 hours; Adults: 3 ± 0.9 hours; Elderly 65 to 75 years of age: 10 ± 7.3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: IM: 30 minutes; IM autoinjector: 3 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (13% to 50% as unchanged drug and metabolites)</p></div>
<div class="block phksp drugH1Div" id="F55170146"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;">Older adult: Elimination half-life is more than doubled.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: AUC and C<sub>max</sub> are 15% higher in females than males; Elimination half-life is ~20 minutes shorter in females than males.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F30124630"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Endotropina | Sulfato de atropina Norgreen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atropinsulfat Aguettant</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulfate aguettant</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Sulfato de atropina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atropin sulfat | Atropinium sulfuricum streuli | Gastril</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropine methobromide</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Atropine accord</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dysurgal | Min-i-jet atropine</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Atropin aguettant | Atropin stragen | Atropine accord</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulfate aguettant</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Atropine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atropinum sulfuricum</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Atropine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulfate aguettant | Atropine sulphate</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Atropine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropine sulphate | Atrothem</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atropina solfato laboratoire aguettant</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Atquick | Atropine</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Atropine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sergal</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulfate aguettant</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Dysurgal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atropin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amixteria</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulf | Atropinesulf | Atropinesulfaat Aguettant</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Atropin aguettant | Atropin stragen</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atroject | Atropine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atropin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sal-tropine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atropina accord | Atropina aguettant | Atropina Labesfal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Atropina sulfato lasca</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Atropin | Atropine nova</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atropin stragen | Atropine accord</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Atropine | Atropine sulphate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Atropina solfato monico | Atropini sulfas</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Atropin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Atropine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Atropin sulfate | Atropine | Bellaton | Soreless | Spanton | Spasmatal | Tromin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Atropin sulfate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Endotropina</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Atropine sulphate | Atropine sulphate fresenius | Pharma q atropine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22351300">
<a name="22351300"></a>Abedin MJ, Sayeed AA, Basher A, Maude RJ, Hoque G, Faiz MA. Open-label randomized clinical trial of atropine bolus injection versus incremental boluses plus infusion for organophosphate poisoning in Bangladesh. <i>J Med Toxicol</i>. 2012;8(2):108-117. doi:10.1007/s13181-012-0214-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/22351300/pubmed" id="22351300" target="_blank">22351300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ATSDR.1">
<a name="ATSDR.1"></a>Agency for Toxic Substances and Disease Registry (ATSDR), “Nerve Agents,” 2011. Available at <a href="https://www.atsdr.cdc.gov/MHMI/mmg166.pdf" target="_blank">http://www.atsdr.cdc.gov/MHMI/mmg166.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi: 10.1067/mpd.2001.116281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AHA.1">
<a name="AHA.1"></a>American Heart Association (AHA). 2015 <i>Handbook of Emergency Cardiovascular Care (ECC) for Healthcare Providers</i>. First American Heart Association Printing. November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AHA.2">
<a name="AHA.2"></a>American Heart Association (AHA). CPR &amp; First Aid: Emergency Cardiovascular Care. Adult Bradycardia Algorithm. https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/algorithms. Published 2020. Accessed January 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15470200">
<a name="15470200"></a>Andriessen P, Janssen BJ, Berendsen RC, et al. Cardiovascular autonomic regulation in preterm infants: the effect of atropine. <i>Pediatr Res</i>. 2004; 56(6):939-946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/15470200/pubmed" id="15470200" target="_blank">15470200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atropen.1">
<a name="Atropen.1"></a>Atropen (atropine) [prescribing information]. St. Louis, MO: Meridian Medical Technologies Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atropine.1">
<a name="Atropine.1"></a>Atropine Ansyr syringe and Lifeshield Abboject syringe [prescribing information]. Lake Forest, IL: Hospira Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanRegent.1">
<a name="AmericanRegent.1"></a>Atropine single-dose vials [prescribing information]. Shirley, NY: American Regent Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Atropine multi-dose vials [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InternationalMedication.1">
<a name="InternationalMedication.1"></a>Atropine sulfate injection [prescribing information]. S El Monte, CA: International Medication Systems, Limited; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PfizerCan.1">
<a name="PfizerCan.1"></a>Atropine sulfate injection 0.1 mg [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AguettantCan.1">
<a name="AguettantCan.1"></a>Atropine sulfate injection prefilled syringes [product monograph]. Montréal, Quebec, Canada: Aguettant Canada Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HikmaCan.1">
<a name="HikmaCan.1"></a>Atropine sulfate solution [product monograph]. Mississauga, Ontario, Canada: Hikma Canada Limited; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21382950">
<a name="21382950"></a>Barrington KJ, "The Myth of a Minimum Dose for Atropine," <i>Pediatrics</i>, 2011, 127(4):783-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/21382950/pubmed" id="21382950" target="_blank">21382950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15114081">
<a name="15114081"></a>Bernheim A, Fatio R, Kiowski W, et al, “Atropine Often Results in Complete Atrioventricular Block or Sinus Arrest After Cardiac Transplantation: An Unpredictable and Dose-Independent Phenomenon,” <i>Transplantation</i>, 2004, 77(8):1181-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/15114081/pubmed" id="15114081" target="_blank">15114081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12598071">
<a name="12598071"></a>Bholasingh R, Cornel JH, Kamp O, et al. Prognostic value of predischarge dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. <i>J Am Coll Cardiol</i>. 2003;41(4):596-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/12598071/pubmed" id="12598071" target="_blank">12598071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1778541">
<a name="1778541"></a>Boudet J, Qing W, Boyer-Chammard A, Del Franco G, Bergougnan JL, Rosen P, Meyer P. Dose-response effects of atropine in human volunteers. <i>Fundam Clin Pharmacol</i>. 1991;5(7):635-640.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/1778541/pubmed" id="1778541" target="_blank">1778541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325359">
<a name="19325359"></a>Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009;37(2):666-688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/19325359/pubmed" id="19325359" target="_blank">19325359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16569248">
<a name="16569248"></a>Camarozano AC, Siqueira-Filho AG, Weitzel LH, Resende P, Noé RA. The effects of early administration of atropine during dobutamine stress echocardiography: advantages and disadvantages of early dobutamine-atropine protocol. <i>Cardiovasc Ultrasound</i>. 2006;4:17. doi:10.1186/1476-7120-4-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/16569248/pubmed" id="16569248" target="_blank">16569248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7125261">
<a name="7125261"></a>Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. <i>Anesthesiology</i>. 1982;57(4):261-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/7125261/pubmed" id="7125261" target="_blank">7125261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19406507">
<a name="19406507"></a>Dart RC, Borron SW, Caravati EM, et al; Antidote Summit Authorship Group. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2009;54(3):386-394.e1. doi:10.1016/j.annemergmed.2009.01.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/19406507/pubmed" id="19406507" target="_blank">19406507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26471384">
<a name="26471384"></a>de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care (Reprint). <i>Pediatrics</i>. 2015;136(Suppl 2:)S176-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/26471384/pubmed" id="26471384" target="_blank">26471384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16464937">
<a name="16464937"></a>Dempsey EM, Al Hazzani F, Faucher D, et al. Facilitation of neonatal endotracheal intubation with mivacurium and fentanyl in the neonatal intensive care unit. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2006; 91(4):F279-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/16464937/pubmed" id="16464937" target="_blank">16464937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14677786">
<a name="14677786"></a>Dix J, Weber RJ, Frye RF, et al. Stability of atropine sulfate prepared for mass chemical terrorism. <i>J Toxicol Clin Toxicol</i>. 2003;41(6):771-775.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/14677786/pubmed" id="14677786" target="_blank">14677786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15533026">
<a name="15533026"></a>Eddleston M, Buckley NA, Checketts H, et al. Speed of initial atropinisation in significant organophosphorus pesticide poisoning - a systematic comparison of recommended regimens. <i>J Toxicol Clin Toxicol</i>. 2004a;42(6):865-875.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/15533026/pubmed" id="15533026" target="_blank">15533026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15566582">
<a name="15566582"></a>Eddleston M, Dawson A, Karalliedde L, et al. Early management after self-poisoning with an organophosphorus or carbamate pesticide – a treatment protocol for junior doctors. <i>Crit Care</i>. 2004b;8(6):R391-R397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/15566582/pubmed" id="15566582" target="_blank">15566582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11320390">
<a name="11320390"></a>Eisenberg MS and Mengert TJ, “Cardiac Resuscitation,” <i>N Engl J Med</i>, 2001, 344(17):1304-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/11320390/pubmed" id="11320390" target="_blank">11320390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Field.1">
<a name="Field.1"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(suppl 3):640-656.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8013509">
<a name="8013509"></a>Fioretti PM, Poldermans D, Salustri A, Forster T, Bellotti P, Boersma E, McNeill AJ, el-Said ES, Roelandt JR. Atropine increases the accuracy of dobutamine stress echocardiography in patients taking beta-blockers. <i>Eur Heart J</i>. 1994;15(3):355-360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/8013509/pubmed" id="8013509" target="_blank">8013509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4621205">
<a name="4621205"></a>Gillick JS. Atropine toxicity in a neonate. <i>Br J Anaesth</i>. 1974;46(10):793-794.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/4621205/pubmed" id="4621205" target="_blank">4621205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldfrank.1">
<a name="Goldfrank.1"></a>Goldfrank LR. Mushrooms. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. New York, NY: McGraw Hill, Inc; 2019;1581-1596.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gropper.1">
<a name="Gropper.1"></a>Gropper M, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Leslie K, eds. <i>Miller's Anesthesia, Volume 1 and 2</i>. 9th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hazinski.2015">
<a name="Hazinski.2015"></a>Hazinski MF, Shuster M, Donnino MW, et al. <i>2015 Handbook of Emergency Cardiovascular Care for Healthcare Providers</i>. South Deerfield, MA: American Heart Association; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA, “Preparing for Pediatric Emergencies: Drugs to Consider,” <i>Pediatrics</i>, 2008, 121(2):433-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26914678">
<a name="26914678"></a>Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. <i>J Nucl Cardiol</i>. 2016;23(3):606-639. doi:10.1007/s12350-015-0387-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/26914678/pubmed" id="26914678" target="_blank">26914678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.1">
<a name="Howland.1"></a>Howland MA. Antidotes in depth – Atropine. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. New York, NY: McGraw Hill, Inc; 2018;1503-1507.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956432">
<a name="20956432"></a>Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Pediatrics</i>. 2010;126(5):e1400-1413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/20956432/pubmed" id="20956432" target="_blank">20956432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2228327">
<a name="2228327"></a>Kentala E, Kaila T, Iisalo E, Kanto J. Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1990;28(9):399-404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/2228327/pubmed" id="2228327" target="_blank">2228327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25455666">
<a name="25455666"></a>King AM, Aaron CK. Organophosphate and carbamate poisoning. <i>Emerg Med Clin North Am</i>. 2015;33(1):133-151.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/25455666/pubmed" id="25455666" target="_blank">25455666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al, “Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kumar.1">
<a name="Kumar.1"></a>Kumar P, Denson SE, Mancuso TJ, et al. Premedication for nonemergency endotracheal intubation in the neonate. <i>Pediatrics</i>. 2010; 125(3):608-615.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26019366">
<a name="26019366"></a>Kumar SS, Jain N, Prakash S, Pawar M. Central anticholinergic syndrome in a neonate operated for tracheoesophageal fistula. <i>Indian J Anaesth</i>. 2015;59(5):330-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/26019366/pubmed" id="26019366" target="_blank">26019366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412709">
<a name="30412709"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2019;74(7):e51-e156. doi:10.1016/j.jacc.2018.10.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/30412709/pubmed" id="30412709" target="_blank">30412709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8772738">
<a name="8772738"></a>Ling LH, Pellikka PA, Mahoney DW, et al. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. <i>J Am Coll Cardiol</i>. 1996;28(3):551-557. doi:10.1016/0735-1097(96)00195-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/8772738/pubmed" id="8772738" target="_blank">8772738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-786681">
<a name="786681"></a>Lonnerholm G, Widerlöv E. Effect of intravenous atropine and methylatropine on heart rate and secretion of saliva in man. <i>Eur J Clin Pharmacol</i>. 1975;8(3-4):233-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/786681/pubmed" id="786681" target="_blank">786681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1615868">
<a name="1615868"></a>McNeill AJ, Fioretti PM, el-Said SM, Salustri A, Forster T, Roelandt JR. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. <i>Am J Cardiol</i>. 1992;70(1):41-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/1615868/pubmed" id="1615868" target="_blank">1615868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7241426">
<a name="7241426"></a>Mirakhur RK, Dundee JW. Comparison of the effects of atropine and glycopyrrolate on various end-organs. <i>J R Soc Med</i>. 1980;73(10):727-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/7241426/pubmed" id="7241426" target="_blank">7241426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7196168">
<a name="7196168"></a>Mirakhur RK, Dundee JW, Jones CJ, Coppel DL, Clarke RS. Reversal of neuromuscular blockade: dose determination studies with atropine and glycopyrrolate given before or in a mixture with neostigmine. <i>Anesth Analg</i>. 1981;60(8):557-562.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/7196168/pubmed" id="7196168" target="_blank">7196168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” <i>Chest</i>, 2003, 123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2758540">
<a name="2758540"></a>Naguib M, Gomaa M. Atropine-neostigmine mixture: a dose-response study. <i>Can J Anaesth</i>. 1989;36(4):412-417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/2758540/pubmed" id="2758540" target="_blank">2758540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122:S729-S767. doi:10.1161/CIRCULATIONAHA.110.970988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472989">
<a name="26472989"></a>Neumar RW, Shuster M, Callaway CW, et al. Part 1: executive summary: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132:S315-S367. doi:10.1161/CIR.0000000000000252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/26472989/pubmed" id="26472989" target="_blank">26472989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12030995">
<a name="12030995"></a>Oei J, Hari R, Butha T, Lui K. Facilitation of neonatal nasotracheal intubation with premedication: a randomized controlled trial. <i>J Paediatr Child Health</i>. 2002;38(2):146-150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/12030995/pubmed" id="12030995" target="_blank">12030995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16 suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31740370">
<a name="31740370"></a>Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. <i>J Am Soc Echocardiogr</i>. 2020;33(1):1-41.e8. doi:10.1016/j.echo.2019.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/31740370/pubmed" id="31740370" target="_blank">31740370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7934540">
<a name="7934540"></a>Picano E, Mathias W Jr, Pingitore A, Bigi R, Previtali M. Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study. Echo Dobutamine International Cooperative Study Group. <i>Lancet</i>. 1994;344(8931):1190-1192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/7934540/pubmed" id="7934540" target="_blank">7934540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28781474">
<a name="28781474"></a>Prakash S, Mullick P. Is a minimum dose of atropine in children justified? <i>J Anaesthesiol Clin Pharmacol</i>. 2017;33(2):282-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/28781474/pubmed" id="28781474" target="_blank">28781474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reigart.1">
<a name="Reigart.1"></a>Reigart JR and Roberts JR, “Recognition and Management of Pesticide Poisonings,” U.S. Environmental Protection Agency, Washington, D.C., 5th edition, 1999: 34-47. Available at <a href="http://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm" target="_blank">http://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15081189">
<a name="15081189"></a>Rizzi RR, Ho J. Post resuscitation central anticholinergic syndrome. <i>Resuscitation</i>. 2004;61(1):101-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/15081189/pubmed" id="15081189" target="_blank">15081189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17379909">
<a name="17379909"></a>Roberts DM and Aaron CK, “Management of Acute Organophosphorus Pesticide Poisoning,” <i>BMJ</i>, 2007, 334(7594):629-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/17379909/pubmed" id="17379909" target="_blank">17379909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23184105">
<a name="23184105"></a>Roberts JR, Karr CJ, Council On Environmental Health. Pesticide exposure in children. <i>Pediatrics</i>. 2012;130(6):e1765-1788.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/23184105/pubmed" id="23184105" target="_blank">23184105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roberts.1">
<a name="Roberts.1"></a>Roberts JR, Reigart JR. Recognition and management of pesticide poisonings. 6th ed. United States Environmental Protection Agency. 2013. Available at <a href="https://www.epa.gov/sites/production/files/documents/rmpp_6thed_ch5_organophosphates.pdf" target="_blank">https://www.epa.gov/sites/production/files/2015-01/documents/rmpp_6thed_final_lowresopt.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17015550">
<a name="17015550"></a>Roberts KD, Leone TA, Edwards WH, et al. Premedication for nonemergent neonatal intubations: a randomized, controlled trial comparing atropine and fentanyl to atropine, fentanyl, and mivacurium. <i>Pediatrics</i>. 2006; 118(4):1583-1591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/17015550/pubmed" id="17015550" target="_blank">17015550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12949297">
<a name="12949297"></a>Rotenberg JS and Newmark J, "Nerve Agent Attacks on Children: Diagnosis and Management," <i>Pediatrics</i>, 2003, 112(3 Pt 1):648-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/12949297/pubmed" id="12949297" target="_blank">12949297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10562483">
<a name="10562483"></a>Santini M, Ammirati F, Colivicchi F, Gentilucci G, Guido V. The effect of atropine in vasovagal syncope induced by head-up tilt testing. <i>Eur Heart J</i>. 1999;20(23):1745-1751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/10562483/pubmed" id="10562483" target="_blank">10562483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29667118">
<a name="29667118"></a>Stolbach A, Bebarta V, Beuhler M, et al. ACMT position statement: alternative or contingency countermeasures for acetylcholinesterase inhibiting agents. <i>J Med Toxicol</i>. 2018;14(3):261-263. doi:10.1007/s13181-018-0658-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/29667118/pubmed" id="29667118" target="_blank">29667118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259635">
<a name="24259635"></a>Stollings JL, Diedrich DA, Oyen LJ, Brown DR. Rapid-sequence intubation: a review of the process and considerations when choosing medications. <i>Ann Pharmacother</i>. 2014;48(1):62-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/24259635/pubmed" id="24259635" target="_blank">24259635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24091052">
<a name="24091052"></a>Thiermann H, Worek F, Kehe K. Limitations and challenges in treatment of acute chemical warfare agent poisoning. <i>Chem Biol Interact</i>. 2013;206(3):435-443. doi:10.1016/j.cbi.2013.09.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/24091052/pubmed" id="24091052" target="_blank">24091052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081526">
<a name="33081526"></a>Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16 Suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/33081526/pubmed" id="33081526" target="_blank">33081526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081526">
<a name="33081526"></a>US Food and Drug Administration (FDA). Search list of extended use dates to assist with drug shortages. <a href="https://www.fda.gov/drugs/drug-shortages/search-list-extended-use-dates-assist-drug-shortages" target="_blank">https://www.fda.gov/drugs/drug-shortages/search-list-extended-use-dates-assist-drug-shortages</a>. Published June 15, 2017. Accessed July 15, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/33081526/pubmed" id="33081526" target="_blank">33081526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8751020">
<a name="8751020"></a>Volz-Zang C, Waldhäuser T, Schulte B, Palm D. Comparison of the effects of atropine in vivo and ex vivo (radioreceptor assay) after oral and intramuscular administration to man. <i>Eur J Clin Pharmacol</i>. 1995;49(1-2):45-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/8751020/pubmed" id="8751020" target="_blank">8751020</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 103678 Version 294.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
